Overview

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Status:
TERMINATED

Trial end date:
2024-02-14

Target enrollment:

Participant gender:

Summary

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with other anti-cancer treatments (in each sub-study), and to establish the recommended Phase 2 dose for each combination treatment to explore in the cohort expansion phase. This study is a sub study of the Master protocol (NCT04126200).

Phase:

PHASE1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

belantamab mafodotin
dostarlimab